In clinical trials of dapagliflozin, mild hypoglycemia has been seen in ∼40% of those treated with dapagliflozin as an add-on to insulin with or without other OADs.19 The lower rate of hypoglycemia observed in this study with dapagliflozin plus insulin may be the result of the short duration of evaluation (4 weeks) versus other studies (24 weeks). Here, INS is linked to Hypoglycemia.